Figure 2.

c-Src contributed to the resistance to paclitaxel under hypoxia. (a) The cell growth inhibition of paclitaxel combined dasatinib assessed by MTT assay. Data had been statistically analyzed by Microsoft Excel 2013 and expressed as means±S.D. for three independent experiments. (b) Cell growth inhibition of paclitaxel on c-Src siRNA transfected cells assessed by MTT assay. Data had been statistically analyzed by Microsoft Excel 2013 and expressed as means±S.D. for three independent experiments. (c) The influence of c-Src siRNA transfection on cell cycle with paclitaxel treatment under hypoxia. Summary of the percentage of cells at G0/G1, S and G2/M phase was performed. (d) The influence of c-Src siRNA transfection on the expression of cylin B1, p-cdc25c, cdc25c, p-CDK1 and CDK1 with paclitaxel treatment under hypoxia. Protein expression change was represented by densitometric analysis. The results are representative of three independent experiments and expressed as means±S.D., **P<0.01, compared with normoxia control groups and ^#P<0.05 and ^##P<0.01, compared with the hypoxia control groups